Literature DB >> 11230481

Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients.

M Wiench1, Z Wygoda, E Gubala, J Wloch, K Lisowska, J Krassowski, D Scieglinska, A Fiszer-Kierzkowska, D Lange, D Kula, M Zeman, J Roskosz, A Kukulska, Z Krawczyk, B Jarzab.   

Abstract

PURPOSE: The study was undertaken to evaluate the frequency of inherited medullary thyroid carcinoma (MTC) among patients with apparent sporadic disease. A stepwise algorithm was used depending on clinical indices and the age of patient at MTC diagnosis. PATIENTS AND METHODS: One hundred sixteen patients with MTC verified by postoperative pathologic examination were subjected to genetic analysis of RET exons 10, 11, 13, 14, and 16 by means of polymerase chain reaction, restriction endonuclease digestion, and DNA sequencing.
RESULTS: Among 116 apparent sporadic MTC patients, we identified eleven (9.5%) RET germline mutation carriers. Seven of these (6.0%) were found by routine analysis (exons 10 and 11). The frequency of inherited disease among patients younger than 45 years at diagnosis was 10.2% by analysis of typical mutations in exons 10 and 11. Extended genetic analysis (sequencing of exons 11, 13, 14, and 16) yielded 6.1% additional diagnoses, giving a risk of 16.3% in this age group. One previously unreported mutation in exon 11 affected codon 649 (TCG>TTG, Ser>Leu). In the true sporadic MTC patients younger than 30 years at diagnosis, frequencies of 36% and 4.5% in polymorphic variants L769L and S836S, respectively, were observed. The frequency for L769L was higher than in older patients (P <.05).
CONCLUSION: The frequency of inherited disease among apparent sporadic medullary thyroid carcinoma patients is close to 10% in the Polish population of MTC patients. The extended analysis of all known RET proto-oncogene mutation sites is obligatory in patients younger than 45 years at diagnosis, but we also see the need to analyze the impact of rarer mutations in older patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230481     DOI: 10.1200/JCO.2001.19.5.1374

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Clinical utility gene card for: multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Susanne Rondot; Egbert Schulze; Sylwia Szpak-Ulczok; Barbara Jarzab; Karin Frank-Raue
Journal:  Eur J Hum Genet       Date:  2011-08-24       Impact factor: 4.246

2.  Hirschsprung's disease and medullary thyroid carcinoma: 15-year experience with molecular genetic screening of the RET proto-oncogene.

Authors:  Eliska Vaclavikova; Lucie Kavalcova; Richard Skaba; Sarka Dvorakova; Pavla Macokova; Blanka Rouskova; Bela Bendlova
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

Review 3.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 4.  Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm.

Authors:  Barbara Jarzab; Jolanta Krajewska
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 5.  Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors.

Authors:  Angela Trepanier; Mary Ahrens; Wendy McKinnon; June Peters; Jill Stopfer; Sherry Campbell Grumet; Susan Manley; Julie O Culver; Ronald Acton; Joy Larsen-Haidle; Lori Ann Correia; Robin Bennett; Barbara Pettersen; Terri Diamond Ferlita; Josephine Wagner Costalas; Katherine Hunt; Susan Donlon; Cecile Skrzynia; Carolyn Farrell; Faith Callif-Daley; Catherine Walsh Vockley
Journal:  J Genet Couns       Date:  2004-04       Impact factor: 2.537

6.  Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

Authors:  Zoran Erlic; Michael M Hoffmann; Maren Sullivan; Gerlind Franke; Mariola Peczkowska; Igor Harsch; Matthias Schott; Helmut E Gabbert; Matti Valimäki; Simon F Preuss; Kornelia Hasse-Lazar; Dariusz Waligorski; Mercedes Robledo; Andrzej Januszewicz; Charis Eng; Hartmut P H Neumann
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

7.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

8.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

9.  Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated?

Authors:  Peter Vestergaard; Else Marie Vestergaard; Helle Brockstedt; Peer Christiansen
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.